Lapatinib Plus Trametinib in KRAS Mutant NSCLC

Inclusion Criteria: * Histological or cytological proof of metastatic NSCLC; for PART B: treated with first line therapy for metastatic disease only. * Written documentation of a known pathogenic KRAS (exon 2, 3 or 4) mutation and PIK3CA wild-type (exon 9 and 20) * Age ≥ 18 years * Able and willing to give written informed consent * WHO performance status of 0 or 1 (part A and B) Exclusion Criteria: * Any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment. * History of another primary malignancy * Symptomatic or untreated leptomeningeal disease * Symptomatic brain metastasis * History of interstitial lung disease or pneumonitis * Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients * Retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), or a history of uveitis, retinal vein occlusion, central serous retinopathy, or retinal detachment * Patients with left ventricular ejection fraction (LVEF) \< 50%